In mouse and human, precursors of NK cell lineage home to decidualizing uteri. To assess the requirement for IL-15, an essential cytokine for NK differentiation in lymphoid tissue, on uterine NK (uNK) cell differentiation, implantation sites from IL-15−/− mice were analyzed histologically. IL-15−/− implantation sites had no uNK cells, no spiral-artery modification, and lacked the decidual integrity found in normal mice. IL-15−/− recipients of C57BL/6 marrow displayed similar pathology. However, implantation sites from recombination-activating gene-2−/−γc−/− (alymphoid) recipients of IL-15−/− marrow showed normal uNK cells, modified spiral arteries, and well-developed decidua basalis. Deletion of the IFN-regulatory factor (IRF)-1, but not IRF-2 (factors important in peripheral NK cell differentiation) limited but did not prevent uNK cell development. In situ hybridization localized IRF-1 largely to placental trophoblast cells. IRF-1−/− marrow transplanted into recombination-activating gene-2−/−γc−/− displayed competence for full uNK cell differentiation. IL-15 mRNA expression at implantation sites of IRF-1−/− and C57BL/6 was similar, suggesting that, unlike in bone marrow and spleen, IRF-1 does not regulate IL-15 in the pregnant uterus. Terminal differentiation of uNK cells was not promoted in pregnant IRF-1−/− mice by 5-day infusion of murine rIL-15, suggesting that IRF-1 deficiency rather than IL-15 deficiency limits uNK cell differentiation in these mice. Further, IRF-1 regulates placental growth, birth weight, and postnatal growth of offspring. These studies indicate that uNK cell development and maturation share some aspects with NK cell development in other tissues, but also display distinctive tissue-specific regulation.

Uterine NK (uNK) 3 cells, an NK cell subset, are the most frequent lymphocytes found within implantation sites during the first half of normal pregnancy in rodents, women, and nonhuman primates (1, 2). In mice, terminally differentiating uNK cells are first recognized at gestation day (gd) 5 (1, 3) in the last region of each implant site to show transformation of fibroblasts to decidual cells, the decidua basalis (DB). uNK cells rapidly increase in number by proliferation in DB, and then in a myometrial region called the mesometrial triangle. By gd 10 of the 19- to 20-day pregnancy, uNK cells form transient, pregnancy-associated mural structures at each implantation site called mesometrial lymphoid aggregates of pregnancy (MLAps) or metrial glands. The MLAps surround the branches of maternal uterine arteries and veins as they enter and leave implantation sites (4). uNK cells are the major but not sole sources of IFN-γ on the mesometrial aspect of each implantation site (5).

The absence of uNK cells in tgε26 (NK, T, B+), IL-2Rβ−/− (NK), and recombination-activating gene-2 (RAG-2)−/−γc−/− (NK, T, B) mice, or absence of IFN-γ signaling in IFN-γ−/−, IFN-γRα−/−, and Stat-1−/− mice during pregnancy is associated with structural stability rather than modification of the branches of the uterine arteries (called decidual spiral arteries (SAs)) that supply the conceptuses. Normal, pregnancy-induced reduction of the vascular smooth muscle coat, and arterial dilation and elongation are restricted (4, 5, 6, 7, 8). In addition to triggering vascular changes, uNK cell-derived IFN-γ promotes the terminal steps in uterine stromal cell transformation into decidua and controls uNK cell maturation (judged by diameter and cytoplasmic granularity) and senescence (7). Mechanisms by which uNK cell-derived IFN-γ exerts these actions are not defined.

In lymphoid organs, IL-15 plays a key role in the maturation of NK progenitor cells (9, 10, 11, 12). The mouse uterus initiates transcription of IL-15 following the onset of decidualization until gd 11, when it is lost (13). IL-15 has been demonstrated in the human uterus throughout the menstrual cycle. Human uterine IL-15 message and protein are elevated in the secretory phase of the menstrual cycle, when decidualization begins (2) and in early pregnancy when decidual tissue is greatly increased (14, 15, 16, 17). Human uterine IL-15 expression is most prominent in perivascular cells surrounding the decidual SA in the late cycle and in the endothelial cells of these arteries during early pregnancy (15). In lymphoid tissue, the transcription factors IFN-regulatory factor (IRF)-1 and IRF-2 regulate NK cell differentiation. IRF-1 binds to promoter sequences in the IL-15 gene, whereas IRF-2 appears to regulate the IL-15R. IRF-1 and IRF-2 are key regulators of IL-12-induced IFN-γ production by NK cells (18, 19, 20, 21). However, uterine IRF-1 is only abundantly expressed in lumenal and glandular epithelium and not uterine stroma in humans (22). This is the same site to which IRF-2 has been localized in the sheep uterus, the only species in which uterine IRF-2 has been investigated (23). Thus, there is circumstantial, but no direct evidence that IL-15 is important for uNK cell differentiation during pregnancy. This is important to establish, because unsuccessful clinical outcomes in human pregnancies are being attributed to imbalance in IL-15 (17). Mice lacking IL-15 (10), IRF-1, and IRF-2 (24) are reproductively competent but have profound reductions in numbers of peripheral NK cells. Implantation sites have not been assessed in these strains to characterize uNK cell differentiation or quantify SA modification. The present study was undertaken to define the role of IL-15 in supporting the differentiation of uNK cells within mouse implantation sites and to address the requirements for IRF-1 and IRF-2 in uNK cell differentiation.

C57BL/6J (B6) and IRF-1−/− mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Breeding pairs of IRF-2−/− and RAG-2−/−γc−/− were kindly provided by Drs. T. Mak (University of Toronto, Toronto, Ontario, Canada) and J. Di Santo (Pasteur Institute, Paris, France). Breeding pairs of IL-15−/− mice were provided by Immunex (Amgen, Thousand Oaks, CA). All strains of knockout mice used in this study were of B6 background. B6 mice were housed under conventional husbandry. All other strains were bred under monitored, barrier husbandry in the University of Guelph (Ontario Ministry of Agriculture, Food, and Rural Affairs Isolation Unit (Guelph, Ontario, Canada)). Females were syngeneically mated. At specific gestation day, counting the copulation plug as day 0, timed-pregnant mice were euthanized by CO2 inhalation, followed by cervical dislocation. Uterine horns were dissected and examined for fetal viability (implant size and color). Only viable implantation sites were chosen for further study. Some of the pregnant B6 and IRF-1−/− mice were permitted to give birth, and their pups were weighed at birth (<12 h), and 21 and 49 days of age.

Implantation sites were fixed in Bouin’s fixative (Fisher Scientific, Whitby, Ontario, Canada) overnight and in 70% ethanol until processed. All fixed tissues were processed into paraffin using standard methodology. Two or three paraffin-embedded implantation sites from each pregnant mouse (four to five pregnant females per study group) were serially sectioned (7 μm) and stained with H&E or periodic acid-Schiff (PAS), which stains the glycoprotein in uNK cell granules. All stained slides were examined by light microscopy. The center section of each serially sectioned implantation site was identified, and for each implantation site, five median tissue sections on each side of the central section were also analyzed (n = 11). Sections were at least 42 μm apart to avoid duplicate counting of individual uNK cells. The number of uNK cells (PAS positive) per square millimeter in the MLAp and in the DB was counted at ×500 magnification using an eyepiece micrometer grid of 1 mm2. The circular smooth muscle was used as the dividing line between the MLAp and DB. Cross-sectional area measurements of the MLAp, decidua, and placenta, and ratios for vessel:lumen diameter line morphometry of the main decidual arteries, cut in cross-section, were measured on the same slides that were used for uNK cell numeration, using OPTIMAS image analysis software, version 6.2 (Optimas, Bothwell, MA).

Six- to 8-wk-old RAG-2−/−γc−/− or IL-15−/− females were used as recipients of BM. Each recipient was pretreated with a single i.p. injection of 5-fluorouracil (150 mg/kg) 48 h before BM infusion. Six- to 8-wk-old IL-15−/−, IRF-1−/−, or B6 mice were used as BM donors. BM cells were pooled from femurs and humeri. Donor cells were depleted of RBC using lysis buffer. A total of 2 × 107 viable BM cells was given i.v. to each 5-fluorouracil-treated female. Three weeks later, recipients were paired with RAG-2−/−γc−/− males for mating and euthanized at gd 12.

Total RNA was isolated from freshly dissected tissue using RNeasy mini kit (Qiagen, Hilden, Germany), according to the manufacturer’s instructions. Two micrograms of total RNA were reverse transcribed using first-strand cDNA synthesis kit (Amersham Pharmacia Biotech, Piscataway, NJ). cDNA were amplified using the following conditions: 94°C for 6 min; 30–35 cycles of 94°C for 45 s, 56°C for 45 s, and 72°C for 45 s; and an extra 7 min at 72°C following the last cycle. The PCR primers were as follows: IL-15–5′, 5′-GCCATAGCCAGCTCATCTTC-3′; IL-15–3′, 5′-GCAATTCCAGGAGAAAGCAG-3′; IRF-2–5′, 5′-ACACTGGAGGAAGAGGAGCA-3′; IRF-2–3′, 5′-CAACAACCACCAGGGAGAGT-3′; β-actin-5′, 5′-GCTACAGCTTCACCACCACA-3′; and β-actin-3′, 5′-ACATCTGCTGGTAGGTGGAC-3′.

For IRF-1 Northern analysis, total RNA was isolated from freshly dissected tissue using the RNeasy mini or midi kits (Qiagen) according to the manufacturer’s instructions. Total RNA from B6 spleen cells, which had been activated with murine (m)rIFN-γ (100 U/ml) and LPS (200 ng/ml) for 6 h was used as positive control. Ten to 20 μg of total RNA were electrophoresed in 1% denaturing agarose-formaldehyde gels and then transferred onto Hybond nylon membranes (Amersham Life Sciences, Oakville, Ontario, Canada) according to standard protocols. Following electroblotting, the RNA was cross-linked by UV irradiation, and the nylon membranes were stored at 4°C until further processing. The mouse IRF-1 (574-bp) probe was generated from clone no. 777393 supplied by GenomeSystems (St. Louis, MO). Radioactive probes were prepared using a commercially prepared Rediprime random-primer DNA-labeling mixture (Amersham International, Buckinghamshire, U.K.). After dissolving the Rediprime mixture and DNA, 50 μCi of radioactive nucleotide [α-32P]dCTP (specific activity, 3000 μCi/mmol; Amersham Life Sciences) was added. The mixture was incubated for 10 min at 37°C. Reactions were stopped by adding 5 μl of 0.2 M EDTA. The radioactive probe was purified by centrifuging 300 μl of TEN through a Quick Spin column (Bio-Rad Laboratories, Hercules, CA) containing 1 ml of Sephadex G-50 at 2000 rpm for 2 min. Membranes supporting the RNA samples were first prehybridized for 1 h at 42°C in a solution containing 5× sodium chloride/sodium phosphate EDTA, 0.5% SDS, 5× Denhardt’s solution, salmon sperm DNA (40 μg/ml), and 50% formamide. Then, the prehybridization buffer was replaced by hybridization buffer containing IRF-1 or 7S probes. Following overnight hybridization at 42°C, membranes were washed twice with low-stringency solution containing 2× SSC and 1% SDS at 42°C for 15 min, followed by a high-stringency wash with 0.1× SSC and 0.1% SDS at 50°C for 10 min. Blots were rinsed in 5× sodium chloride/sodium phosphateEDTA, and the hybridization signal was detected by autoradiography, using Kodak (Rochester, NY) x-ray film. For IL-15, total RNA extracted by the guanidinium isothiocyanate method (25) was analyzed by Northern blot hybridization as described, including stringent posthybridization washes (26). Each lane contained 10 μg of total RNA. [32P]cRNA probes were generated from a ribovector containing mIL-15 cDNA, generously supplied by A. Troutt (Immunex, Seattle, WA).

In situ hybridization was performed on paraffin-embedded sections of nonpregnant gestation day-timed uteri from B6 and alymphoid mice. Clone no. 777393 (supplied by GenomeSystems) was used for the mouse IRF-1 (574-bp) probe. Digoxigenin-labeled IRF-1 sense and antisense probes were made using Northern starter kit, according to the manufacturer’s instructions (Roche, Montreal, Quebec, Canada). In situ hybridization on 8-μm sections was performed according to the nonradioactive in situ hybridization application manual (Roche). For the visualization of the RNA probe, the sections were incubated with 5-bromo-4-chloro-3-indolyl phosphate/nitroblue tetrazolium liquid substrate system (Sigma-Aldrich, Oakville, Ontario, Canada) for up to 24 h.

IRF-1−/− mice received 500 ng of mrIL-15 (Research Diagnostics, Flanders, NJ) i.p., daily for 5 days, from gd 5. On gd 10, pregnant uteri were dissected and processed for analysis. The dosage and route of mrIL-15 were selected based on previous in vivo experiments (10, 27).

The means of experimental groups were compared using two-factor ANOVA. The between-mice and the between-implantation sites variances were considered as analytic factors (p < 0.05). Groups with significantly different means were identified using Tukey’s test (p < 0.05). Pup weights were compared by paired t test.

IL-15 is essential for NK cell development in lymphoid tissue. Implantation sites of IL-15−/− mice differed from normal mice in that they completely lacked uNK cells. In addition, IL-15−/− mice did not develop MLAp, had exceedingly hypocellular DB, and failed to modify SA (Fig. 1, a vs c). The latter features resemble those seen in alymphoid mice (Fig. 1 b) but are more pronounced. Placental cross-sectional areas in IL-15−/− mice were similar to those in time-matched normal controls (data not shown), and no elevated fetal loss (fetal loss, 2.3%; mean litter size, 8.2) was observed.

FIGURE 1.

Implantation site anomalies in the absence of uNK cells. Photomicrographs of implantation sites from gd 12 mice. IL-15−/− mice (a and a2) and RAG-2−/−γc−/− (b and b2) are genetically devoid of uNK cells. MLAp structure does not develop in the myometrial wall of these mice. The implantation site in the normal C57BL/6 congenic controls shows development of uNK cells, as indicated by arrows, and MLAp (c and c2). Implantation sites of mice lacking uNK cells possess unmodified decidual spiral arteries, characterized by a thicker blood vessel wall (a1 and b1, compared with c1) and higher wall:lumen ratios. The DB is also hypocellular (a and b) compared with the C57BL/6 control (c). The uNK cell-positive C57BL/6 mouse has modified SAs, showing a much thinner blood vessel wall (c1). SAs in the C57BL/6 control are considered to be modified, whereas those arteries in mice without uNK cells retain the appearance of those in a virgin uterus. Arterial modification in C57BL/6 occurs between gd 9.5 and 10.0. Sections were stained with PAS. M, Myometrium. a–c, ×25; a1, a2, b1, b2, c1, and c2, ×400.

FIGURE 1.

Implantation site anomalies in the absence of uNK cells. Photomicrographs of implantation sites from gd 12 mice. IL-15−/− mice (a and a2) and RAG-2−/−γc−/− (b and b2) are genetically devoid of uNK cells. MLAp structure does not develop in the myometrial wall of these mice. The implantation site in the normal C57BL/6 congenic controls shows development of uNK cells, as indicated by arrows, and MLAp (c and c2). Implantation sites of mice lacking uNK cells possess unmodified decidual spiral arteries, characterized by a thicker blood vessel wall (a1 and b1, compared with c1) and higher wall:lumen ratios. The DB is also hypocellular (a and b) compared with the C57BL/6 control (c). The uNK cell-positive C57BL/6 mouse has modified SAs, showing a much thinner blood vessel wall (c1). SAs in the C57BL/6 control are considered to be modified, whereas those arteries in mice without uNK cells retain the appearance of those in a virgin uterus. Arterial modification in C57BL/6 occurs between gd 9.5 and 10.0. Sections were stained with PAS. M, Myometrium. a–c, ×25; a1, a2, b1, b2, c1, and c2, ×400.

Close modal

To determine whether IL-15 was the sole limitation to uNK cell differentiation in IL-15−/− mice, IL-15−/− BM was transplanted into alymphoid mice, and B6 BM was transplanted into IL-15−/− or alymphoid recipients. Transplanted females were mated to nontransplanted, syngeneic males, and gd 12 implantation sites were studied. uNK cells differentiated from IL-15−/− BM and B6 BM in alymphoid mice to numbers equivalent to those found in normal mice. An MLAp developed, decidua became highly cellular, and arterial change was induced. However, transplanted B6 BM failed to give rise to uNK cells in pregnant IL-15−/− hosts, no MLAp was present, decidual hypocellularity persisted, and arterial change was not induced (Figs. 2 and 3). Implantation sites of alymphoid mice were positive for IL-15 mRNA (Fig. 2 d)

FIGURE 2.

IL-15 is the key molecule for uNK cell differentiation and maturation. Photomicrographs of gd 12 implantation sites in BM transfer recipients. a, In RAG-2−/−γc−/− recipients of IL-15−/− marrow, fully differentiated uNK cells are found in abundance (a1), and SA dilation occurs (a2). b, In IL-15−/− recipients of C57BL/6 marrow, no uNK cell differentiation occurs (b1), and no modification of recipient arteries occurs (b2). c, In RAG-2−/−γc−/− recipients of C57BL/6 marrow, uNK cell differentiation (c1) and SA modification (c2) occur. Precursor cells receiving IL-15 signals differentiate into uNK cells. The MLAp of uNK containing implantation sites is well developed. d, IL-15 mRNA was detected by RT-PCR at the implantation sites of RAG-2−/−γc−/− mice. Lane 1, DNA ladder; lane 2, nonpregnant uterus; lane 3, DB; and lane 4, placenta from gd 10. Sections were stained with PAS. a–c, ×25; a1, a2, b1, b2, c1, and c2, ×400.

FIGURE 2.

IL-15 is the key molecule for uNK cell differentiation and maturation. Photomicrographs of gd 12 implantation sites in BM transfer recipients. a, In RAG-2−/−γc−/− recipients of IL-15−/− marrow, fully differentiated uNK cells are found in abundance (a1), and SA dilation occurs (a2). b, In IL-15−/− recipients of C57BL/6 marrow, no uNK cell differentiation occurs (b1), and no modification of recipient arteries occurs (b2). c, In RAG-2−/−γc−/− recipients of C57BL/6 marrow, uNK cell differentiation (c1) and SA modification (c2) occur. Precursor cells receiving IL-15 signals differentiate into uNK cells. The MLAp of uNK containing implantation sites is well developed. d, IL-15 mRNA was detected by RT-PCR at the implantation sites of RAG-2−/−γc−/− mice. Lane 1, DNA ladder; lane 2, nonpregnant uterus; lane 3, DB; and lane 4, placenta from gd 10. Sections were stained with PAS. a–c, ×25; a1, a2, b1, b2, c1, and c2, ×400.

Close modal
FIGURE 3.

uNK cells contribute to SA modification. Histograms are presented to summarize the morphometric analyses. a, The complete absence of uNK cells in RAG-2−/−γc−/− mice, IL-15−/− mice, and IL-15−/− recipients of C57BL/6 BM is indicated. In contrast, large numbers of uNK cells are present in RAG-2−/−γc−/− recipients of C57BL/6 or IL-15−/− BM, and these are equivalent to numbers in B6 implantation sites. Absence of uNK cells is shown by x. b, Vessel-to-lumen diameter measurements are presented. These ratios were similar at gd 12 in the strains without uNK cells (RAG-2−/−γc−/−, IL-15−/−, C57BL/6 BM-engrafted IL-15−/−). Lower ratios, indicative of wall thinning and lumen diameter increase, were induced by cells derived from IL-15−/− or C57BL/6 BM grafts in RAG-2−/−γc−/− mice. Data were compiled from 11 measurements per implantation site (four to five mothers per group; two to three implantation sites per mother).

FIGURE 3.

uNK cells contribute to SA modification. Histograms are presented to summarize the morphometric analyses. a, The complete absence of uNK cells in RAG-2−/−γc−/− mice, IL-15−/− mice, and IL-15−/− recipients of C57BL/6 BM is indicated. In contrast, large numbers of uNK cells are present in RAG-2−/−γc−/− recipients of C57BL/6 or IL-15−/− BM, and these are equivalent to numbers in B6 implantation sites. Absence of uNK cells is shown by x. b, Vessel-to-lumen diameter measurements are presented. These ratios were similar at gd 12 in the strains without uNK cells (RAG-2−/−γc−/−, IL-15−/−, C57BL/6 BM-engrafted IL-15−/−). Lower ratios, indicative of wall thinning and lumen diameter increase, were induced by cells derived from IL-15−/− or C57BL/6 BM grafts in RAG-2−/−γc−/− mice. Data were compiled from 11 measurements per implantation site (four to five mothers per group; two to three implantation sites per mother).

Close modal

Because IRF-1 is thought to be essential for IL-15 expression in BM (Ogasawara et al., 1998), and both IRF-1 and -2 are important for NK cell development in marrow, implantation sites of IRF-1−/− and IRF-2−/− mice were studied. They had no elevated fetal loss (fetal loss, 4.63%) compared with their congenic control. IRF-2−/− sites did not differ histologically from implantation sites in normal mice (Fig. 4,b), although RT-PCR showed that IRF-2 was abundantly expressed in virgin and pregnant uteri of B6 and alymphoid mice (d). In contrast, in IRF-1−/− mice after gd 6, implantation sites were smaller grossly and in histologic cross-sectional area than in time-matched B6 controls (Figs. 4,a and 5). uNK cells differentiated in IRF-1−/− mice but were few in number, small, and hypogranular. In addition, MLAp regions were poorly developed, and SA failed to modify (Fig. 4 a).

FIGURE 4.

IRF-1, but not IRF-2, is important for completion of uNK cell development. Photomicrographs of implantation sites of gd 12. a, IRF-1−/− mice have some uNK cells that appear poorly differentiated due to their small diameter and cytoplasmic hypogranularity (a2), unmodified SAs (a1), hypocellular DB, and an underdeveloped MLAp (a). b, IRF-2−/− mice appear similar to genetically normal mice. They differentiate large numbers of uNK cells (b2), undergo SA modification (b1), and develop a normal MLAp. c, Northern analysis for IRF-1 mRNA shows no expression on the mesometrial side of implantation sites from alymphoid and C57BL/6 mice. Lane 1, gd 6 mesometrial triangle RNA; lanes 2 and 3, gd 10 MLAp RNA from B6; lanes 4 and 5, gd 6 and 10 RNA from RAG-2−/−γc−/− mice, respectively; lanes 6 and 7, liver; and lane 8, spleen cells treated with IFN-γ and LPS for 6 h as positive control. d, RT-PCR for IRF-2 mRNA. Lanes 2–6 are from B6 mice, and lanes 7–10 are from RAG-2−/−γc−/− mice. M, DNA ladder; lane 1, negative control (PCR of RNA without reverse transcription); lane 2, nonpregnant uterus; lane 3, gd 6; lanes 4–6, gd 10 MLAp, DB, and placenta, respectively; lane 7, nonpregnant uterus; lane 8, gd 6; lanes 9 and 10, gd 10 DB and placenta, respectively. e1, In situ hybridization for IRF-1 mRNA in C57BL/6 mice. In the nonpregnant uterus, IRF-1 is found in uterine and glandular epithelial cells (e, as indicated by arrows, and e1). At gd 8, very strong hybridization was found on trophoblast giant cells (j and k, arrows, show positive cells). g, At gd 10, giant cells remained heavily labeled. f, Other placental cells were also positive, as were uterine epithelial cells adjacent to and at the antimesometrial aspect of the implantation sites. h, MLAp was negative, but signal was observed in dispersed decidual cells and SA walls. l, Sense probe negative control. a, a1, a2, b, b1, and b2, Sections were stained with PAS. a and b, ×25; a1, a2, b1, and b2, ×400.

FIGURE 4.

IRF-1, but not IRF-2, is important for completion of uNK cell development. Photomicrographs of implantation sites of gd 12. a, IRF-1−/− mice have some uNK cells that appear poorly differentiated due to their small diameter and cytoplasmic hypogranularity (a2), unmodified SAs (a1), hypocellular DB, and an underdeveloped MLAp (a). b, IRF-2−/− mice appear similar to genetically normal mice. They differentiate large numbers of uNK cells (b2), undergo SA modification (b1), and develop a normal MLAp. c, Northern analysis for IRF-1 mRNA shows no expression on the mesometrial side of implantation sites from alymphoid and C57BL/6 mice. Lane 1, gd 6 mesometrial triangle RNA; lanes 2 and 3, gd 10 MLAp RNA from B6; lanes 4 and 5, gd 6 and 10 RNA from RAG-2−/−γc−/− mice, respectively; lanes 6 and 7, liver; and lane 8, spleen cells treated with IFN-γ and LPS for 6 h as positive control. d, RT-PCR for IRF-2 mRNA. Lanes 2–6 are from B6 mice, and lanes 7–10 are from RAG-2−/−γc−/− mice. M, DNA ladder; lane 1, negative control (PCR of RNA without reverse transcription); lane 2, nonpregnant uterus; lane 3, gd 6; lanes 4–6, gd 10 MLAp, DB, and placenta, respectively; lane 7, nonpregnant uterus; lane 8, gd 6; lanes 9 and 10, gd 10 DB and placenta, respectively. e1, In situ hybridization for IRF-1 mRNA in C57BL/6 mice. In the nonpregnant uterus, IRF-1 is found in uterine and glandular epithelial cells (e, as indicated by arrows, and e1). At gd 8, very strong hybridization was found on trophoblast giant cells (j and k, arrows, show positive cells). g, At gd 10, giant cells remained heavily labeled. f, Other placental cells were also positive, as were uterine epithelial cells adjacent to and at the antimesometrial aspect of the implantation sites. h, MLAp was negative, but signal was observed in dispersed decidual cells and SA walls. l, Sense probe negative control. a, a1, a2, b, b1, and b2, Sections were stained with PAS. a and b, ×25; a1, a2, b1, and b2, ×400.

Close modal
FIGURE 5.

Absence of IRF-1 leads to smaller placenta and lower pup weight. Photomicrographs of implantation sites from gd 12 and 14 mice. a and b, In the IRF-1−/− mice, placental growth is impaired compared with age-matched C57BL/6 controls (c and d). e, IRF-1−/− placental cross-sectional area is significantly smaller than that of age-matched controls. f and g, Weights of neonatal (<12 h), prepubescent (21 days), and adult (49 days) IRF-1−/− mice are significantly less than those of age-matched C57BL/6 controls. Sections were stained with PAS. a–d, ×20. P, Placenta.

FIGURE 5.

Absence of IRF-1 leads to smaller placenta and lower pup weight. Photomicrographs of implantation sites from gd 12 and 14 mice. a and b, In the IRF-1−/− mice, placental growth is impaired compared with age-matched C57BL/6 controls (c and d). e, IRF-1−/− placental cross-sectional area is significantly smaller than that of age-matched controls. f and g, Weights of neonatal (<12 h), prepubescent (21 days), and adult (49 days) IRF-1−/− mice are significantly less than those of age-matched C57BL/6 controls. Sections were stained with PAS. a–d, ×20. P, Placenta.

Close modal

To assess whether small placental size affected fetal and/or postnatal development, IRF-1−/− litters were weighed at birth, weaning (21 days), and adulthood (49 days). Neonates were significantly smaller than barrier husbandry-reared, age-matched B6, and weight deficits persisted into adulthood (Fig. 5).

Microarray (GEM; Incyte, St. Louis, MO) data, based upon RNA collected from mesometrial triangles of B6 mice on gd 6 and MLAps on gd 10, showed no IRF-1 expression (our unpublished observations). This was confirmed by Northern analyses conducted on microdissected mesometrial triangle (gd 6) and MLAp (gd 10) regions from B6 and alymphoid mice (Fig. 4,c). To localize the microdomains of IRF-1 expression within implantation sites, in situ hybridization was conducted on virgin and pregnant uteri from B6 and alymphoid mice. In both strains, signals in virgin uteri were localized to the lumenal and glandular epithelia (Fig. 4, e and e1). At gd 8, in both strains, very strong hybridization was found in trophoblast giant cells (Fig. 4, j and k). At gd 10, giant cells remained heavily labeled (Fig. 4,g). The now mature placenta was also positive, as were the uterine epithelial cells adjacent to and at the antimesometrial aspect of the implantation sites (Fig. 4,f). The uNK cell-rich MLAp was negative, but signal was observed in dispersed decidual cells and SA walls (Fig. 4 h).

To determine whether IRF-1−/− uNK precursors are competent for normal maturation and numerical expansion in an IRF-1+/+ uterine environment, alymphoid mice were engrafted with BM from IRF-1−/− mice. This established terminally differentiated uNK cells in recipients’ implantation sites (Fig. 6,a; compare with c for normal control, d for nonengrafted host, and f for donor implantation sites). Reconstitution of alymphoid mice by IRF-1−/− BM induced MLAp development and reversed the anomalies in the decidua and its arteries seen in implantation sites of untreated hosts (Fig. 6, compare b with e). Quantification showed that IRF-1−/− BM reconstituted uNK cell numbers to those observed in B6 (Fig. 6 g).

FIGURE 6.

BM from IRF-1−/− mice is competent to restore uNK cells in an IRF-1-positive environment. Gestation day 12 implantation site photomicrographs. RAG-2−/−γc−/− mice possess no uNK cells (d) and have unmodified SAs (e). Transferring IRF-1−/− BM into RAG-2−/−γc−/− mice restores uNK cell proliferation and differentiation (a) compared with BM from B6 (c) and from IRF-1−/− (f). SAs of IRF-1−/− BM recipient mice are modified compared with unmanipulated RAG-2−/−γc−/− (b and e). g, IRF-1−/− mice are significantly deficient of uNK cells. Transplantation of IRF-1−/− marrow into RAG-2−/−γc−/− mice restores uNK cell frequency to control values. Sections were stained with PAS and magnified ×200.

FIGURE 6.

BM from IRF-1−/− mice is competent to restore uNK cells in an IRF-1-positive environment. Gestation day 12 implantation site photomicrographs. RAG-2−/−γc−/− mice possess no uNK cells (d) and have unmodified SAs (e). Transferring IRF-1−/− BM into RAG-2−/−γc−/− mice restores uNK cell proliferation and differentiation (a) compared with BM from B6 (c) and from IRF-1−/− (f). SAs of IRF-1−/− BM recipient mice are modified compared with unmanipulated RAG-2−/−γc−/− (b and e). g, IRF-1−/− mice are significantly deficient of uNK cells. Transplantation of IRF-1−/− marrow into RAG-2−/−γc−/− mice restores uNK cell frequency to control values. Sections were stained with PAS and magnified ×200.

Close modal

Because BM cells from IL-15−/− and IRF-1−/− mice differentiate into uNK cells in alymphoid mice, presence of IL-15 in the recipient uteri was anticipated. Uterine mRNA from virgin and pregnant alymphoid, IRF-1−/− and B6 mice was assessed for IL-15. RT-PCR, Northern (Fig. 7), and RNase protection assays (not shown) all indicated that mRNA for IL-15 was induced after uterine decidualization in the three strains. Attempts to address IL-15 at the protein level were unsuccessful.

FIGURE 7.

IL-15 mRNA is found at implantation sites of C57BL/6 and IRF-1−/− mice. Total RNA was isolated from implantation sites on different days of gestation and from other tissues and analyzed for IL-15 mRNA expression. a, IL-15 mRNA was detected in nonpregnant uterus (gd −1) from all three strains of mice. The IL-15 message was weaker in IRF-1−/− than B6 spleen. SP; spleen; PL; placenta; control indicates RNA with no reverse transcription. b, Upper panel, Northern blot for IL-15 mRNA from implantation sites of IRF-1−/− and B6 mice at gd 8 (D8) and 12 (D12) (B6 mice had the same pattern of mRNA expression seen in IRF-1−/− mice). IL-15 mRNA in DB and placenta were much lower at gd 12 compared with gd 10. M, MLAp; D, DB; P, placenta. b, Lower panel, An ethidium bromide-stained gel is shown.

FIGURE 7.

IL-15 mRNA is found at implantation sites of C57BL/6 and IRF-1−/− mice. Total RNA was isolated from implantation sites on different days of gestation and from other tissues and analyzed for IL-15 mRNA expression. a, IL-15 mRNA was detected in nonpregnant uterus (gd −1) from all three strains of mice. The IL-15 message was weaker in IRF-1−/− than B6 spleen. SP; spleen; PL; placenta; control indicates RNA with no reverse transcription. b, Upper panel, Northern blot for IL-15 mRNA from implantation sites of IRF-1−/− and B6 mice at gd 8 (D8) and 12 (D12) (B6 mice had the same pattern of mRNA expression seen in IRF-1−/− mice). IL-15 mRNA in DB and placenta were much lower at gd 12 compared with gd 10. M, MLAp; D, DB; P, placenta. b, Lower panel, An ethidium bromide-stained gel is shown.

Close modal

To further address whether anomalies at the implantation sites of IRF-1−/− mice were due to IL-15 protein deficiency, mrIL-15 was administered for 5 days to pregnant IRF-1−/− mice. Treatment did not induce changes to IRF-1−/− implantation sites. The uNK cell population remained immature and was not increased in number. MLAp was not induced, and no significant changes were induced in SA or placental size from mrIL-15 treatment of IRF-1−/− mice compared with untreated controls (Table I).

Table I.

mrIL-15 failed to restore implantation site anomalies in IRF-1−/− mice

No. of uNK Cells ± SEMVessel:Lumen Ratios of SA ± SEMPlacental Cross-Sectional Area (mm2) ± SEM
MLApDB
IRF-1−/−+ mrIL-15 17.4 ± 3.57a 19.4 ± 4.01a 2.19 ± 0.22a 9.6 ± 1.70a 
IRF-1−/−+ PBS 16.3 ± 3.72b 20.1 ± 4.13b 2.08 ± 0.24b 9.0 ± 1.58b 
B6 control 64.6 ± 7.21 38.7 ± 4.63 1.19 ± 0.19 18.7 ± 2.04 
No. of uNK Cells ± SEMVessel:Lumen Ratios of SA ± SEMPlacental Cross-Sectional Area (mm2) ± SEM
MLApDB
IRF-1−/−+ mrIL-15 17.4 ± 3.57a 19.4 ± 4.01a 2.19 ± 0.22a 9.6 ± 1.70a 
IRF-1−/−+ PBS 16.3 ± 3.72b 20.1 ± 4.13b 2.08 ± 0.24b 9.0 ± 1.58b 
B6 control 64.6 ± 7.21 38.7 ± 4.63 1.19 ± 0.19 18.7 ± 2.04 
a

No significant differences when compared with those of IRF-1−/− mice (PBS control), but significantly different compared with B6 control, p < 0.006.

b

No significant differences when compared with those of IRF-1−/− mice treated with mrIL-15, but significantly different compared with B6 control, p < 0.005.

These studies clearly demonstrate that IL-15 is absolutely essential for the support of NK cell differentiation in the decidualizing uterus. Analyses of implantation sites in IL-15−/− mice revealed a complete absence of uNK cells as well as pathology consistent with that seen in other strains severely or totally deficient in uNK cells. The features included unmodified SA structure, poor development of decidua, and absence of MLAp development within the uterine wall. These features do not compromise fetal viability or postnatal survival under microbiological barrier husbandry and are assumed to negatively reflect the major functions of uNK cells. No measures of fetal stress or postnatal physiology were performed.

The time course for transcription of mouse uterine IL-15 expression (13) mirrors that for development of uNK cells. Rare cells are first found at gd 5 with significant numbers on gd 6 when IL-15 message is first reported. uNK cells proliferate within mouse uterus from gd 6 to midgestation, achieve relatively stable peak numbers between gd 10 and 12, and then gradually decline in numbers (3, 28). IL-15 message in decidua is found to gd 11 and is then absent to term (13). Withdrawal of IL-15 would be the simplest explanation for the disappearance of uNK cells. IL-15 withdrawal is likely gradual due to transendosomal cycling providing persistent surface-bound IL-15 in decidual stroma (29). Just before parturition, ∼10% of the peak uNK cell number remains. These cells are shed with the placenta (28). Induction of IL-15 transcription in SA endothelium, as seen in women, may also occur in mice. This could account for the highly localized appearance of intravascular uNK cells within the component of the SA coursing through the decidua (1, 30, 31) and for uNK cell absence from more superficial segments of the same vessels within the MLAp (32). This positional relationship may be of major functional importance in elongation and dilation of SA, because both mouse and human uNK cells express endothelial cell mitogens and other vasoactive molecules such as inducible NO synthase (33, 34)

If IL-15 is the only growth factor essential for uNK cell differentiation, as suggested by our marrow transplants, IL-15 regulation within uterus becomes an important question. In marrow, IRF-1 appears to be a key transcriptional activation factor for IL-15 (20). Implantation sites in IRF-1−/− mice differ from those in any other mouse strain reported to date. The uNK cell lineage was established, but it failed to fully differentiate numerically or morphologically. Furthermore, a major role for IRF-1 in trophoblast, particularly giant-cell, biology was defined. Over a period of 3 years, no drift was seen in the IRF-1−/− phenotype of small placentae and small size of offspring. Small placentae may be the primary cause of the intrauterine growth retardation, or there may be additional primary deficits in fetuses as themselves during development. The lasting effect of this gene deletion into adulthood suggests that IRF-1−/− mice maybe a convenient model to address postnatal outcomes in growth-restricted humans (35). Consistent with other in vitro and in vivo models evaluating differentiation of NK cells, moving marrow cells from IRF-1−/− to a normal stromal environment, showed that the gene deletion did not impair the differentiation capacity of uNK progenitor cells.

Limited differentiation of uNK cells in the IRF-1-free environment suggested that some IL-15 was present in the uteri of IRF-1−/− mice that could interact with the high-affinity IL-15R on uNK progenitor cells (6, 36). This was supported at the level of IL-15 gene transcription and by the inability of exogenous IL-15 treatment to normalized IRF-1−/− implantation sites. Thus, IRF-1 in a normal mouse may regulate expression of genes involved in recruitment of uNK cell precursors to the uterus (37), or it may act indirectly in stromal-derived cytokine support of terminal uNK cell differentiation steps. Vascular addressin VCAM could be a key IRF-1-regulated recruitment molecule (38). VCAM has unique expression in DB and is postulated to be the major addressin homing NK cells to the uterus (31, 37). IRF-1 also contributes to vascular remodeling events where it is antagonized by IRF-2 (39, 40). IRF-2 appears to be an enhancer of VCAM-1 expression in myogenic events outside of the vasculature (41).

Endocrine control of IRF-1 and IL-15 gene expression has been proposed in human uterus and may account for the absence of IRF-1 regulation of murine uterine IL-15. Prolactin, a pituitary hormone, is thought to enhance IRF-1 expression (42), whereas progesterone and PG, derived from ovary and placenta, are proposed as regulators of IL-15 expression (14, 15, 16). However, these mechanisms fail to explain regulation of NK cell differentiation in decidua, because the hormone effects are present systemically. Thus, additional unique regulatory mechanisms must be involved in IL-15 expression in decidualizing uterus.

The results of this study suggest that uNK cell development and maturation have aspects similar to NK cell development in other tissues but, in addition, have distinct differences. The absence of IL-15 leads to the absence of both uNK and NK cells, whereas absence of IRF-1 results in partial deficiency of uNK and complete deficiency of NK cells. In the absence of IRF-2, uNK cells are normal in number and function, but there is a severe deficiency of peripheral NK cells. This may suggest tissue-specific regulation of IL-15 in uterine stromal cells. Unique, IRF-1-regulated decidual cytokines may account for the skewing of NK cells features seen in uterine compared with peripheral sites.

We thank Immunex, Inc., for providing the IL-15 cDNA probe and permission to receive breeding pairs of IL-15−/− mice from Dr. M. Caligiuri (Ohio State University, School of Medicine, Columbus, OH); Dr. T. W. Mak for providing IRF-1−/− and breeding pairs of IRF-2−/− mice; Lorena Montoya, Martha Brackin, and the Ontario Ministry of Agriculture, Food, and Rural Affairs Isolation staff for their technical support.

1

These studies were supported by Natural Sciences and Engineering Research Council; Ontario Ministry of Agriculture, Food, and Rural Affairs; National Institutes of Health (HD32552); and Ministry of Science, Research, and Technology of Iran.

3

Abbreviations used in this paper: uNK, uterine NK; gd, gestation day; DB, decidua basalis; MLAp, mesometrial lymphoid aggregate of pregnancy; RAG, recombination-activating gene; SA, spiral artery; IRF, IFN-regulatory factor; PAS, periodic acid-Schiff; BM, bone marrow; m, murine.

1
Peel, S..
1989
. Granulated metrial gland cells.
Adv. Anat. Embryol. Cell Biol.
115
:
1
.
2
Moffett-King, A..
2002
. Natural killer cells and pregnancy.
Nat. Rev. Immunol.
2
:
656
.
3
Paffaro, V. A., M. C. Bizinotto, P. P. Joazerio, A. T. Yamada.
2003
. Subset classification of mouse uterine natural killer cells by DBA lectin reactivity.
Placenta
24
:
479
.
4
Guimond, M. J., B. Wang, B. A. Croy.
1998
. Engraftment of bone marrow from severe combined immunodeficient (SCID) mice reverses the reproductive deficits in natural killer cell-deficient tg epsilon 26 mice.
J. Exp. Med.
187
:
217
.
5
Ashkar, A. A., B. A. Croy.
1999
. Interferon-γ contributes to the normalcy of murine pregnancy.
Biol. Reprod.
61
:
493
.
6
Guimond, M. J., J. A. Luross, B. Wang, C. Terhorst, S. Danial, B. A. Croy.
1997
. Absence of natural killer cells during murine pregnancy is associated with reproductive compromise in TgE26 mice.
Biol. Reprod.
56
:
169
.
7
Ashkar, A. A., J. P. Di Santo, B. A. Croy.
2000
. Interferon-γ contributes to initiation of uterine vascular modification, decidual integrity, and uterine natural killer cell maturation during normal murine pregnancy.
J. Exp. Med.
192
:
259
.
8
Croy, B. A., S. Esadeg, S. Chantakru, M. Van den Heuvel, V. A. Paffaro, H. He, G. P. Black, A. A. Ashkar, Y. Kiso, J. Zhang.
2003
. Update on pathways regulation the activation of uterine natural killer cells, their interactions with decidual apriral arteries and homing of their precursors to the uterus.
J. Reprod. Immunol.
59
:
175
.
9
Carson, W. E., T. A. Fehniger, S. Haldar, K. Eckhert, M. J. Lindemann, C. F. Lai, C. M. Croce, H. Baumann, M. A. Caligiuri.
1997
. A potential role for interleukin-15 in the regulation of human natural killer cell survival.
J. Clin. Invest.
99
:
937
.
10
Kennedy, M. K., M. Glaccum, S. N. Brown, E. A. Butz, J. L. Viney, M. Embers, N. Matsuki, K. Charrier, L. Sedger, C. R. Willis, et al
2000
. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice.
J. Exp. Med.
191
:
771
.
11
Puzanov, I. J., M. Bennett, V. Kumar.
1996
. IL-15 can substitute for the marrow microenvironment in the differentiation of natural killer cells.
J. Immunol.
157
:
4282
.
12
Rosmaraki, E. E., I. Douagi, C. Roth, F. Colucci, A. Cumano, J. P. Di Santo.
2001
. Identification of committed NK cell progenitors in adult murine bone marrow.
Eur. J. Immunol.
31
:
1900
.
13
Ye, W., L. M. Zheng, J. D. Young, C. C. Liu.
1996
. The involvement of interleukin (IL)-15 in regulating the differentiation of granulated metrial gland cells in mouse pregnant uterus.
J. Exp. Med.
184
:
2405
.
14
Okada, S., H. Okada, M. Sanezumi, T. Nakajima, K. Yasuda, H. Kanzaki.
2000
. Expression of interleukin-15 in human endometrium and decidua.
Mol. Hum. Reprod.
6
:
75
.
15
Kitaya, K., J. Yasuda, I. Yagi, Y. Tada, S. Fushiki, H. Honjo.
2000
. IL-15 expression at human endometrium and decidua.
Biol. Reprod.
63
:
683
.
16
Dunn, C. L., H. O. Critchley, R. W. Kelly.
2002
. IL-15 regulation in human endometrial stromal cells.
J. Clin. Endocrinol. Metab.
87
:
1898
.
17
Chegini, N., C. Ma, M. Roberts, R. S. Williams, B. A. Ripps.
2002
. Differential expression of interleukins (IL) IL-13 and IL-15 throughout the menstrual cycle in endometrium of normal fertile women and women with recurrent spontaneous abortion.
J. Reprod. Immunol.
56
:
93
.
18
Duncan, G. S., H. W. Mittrucker, D. Kagi, T. Matsuyama, T. W. Mak.
1996
. The transcription factor interferon regulatory factor-1 is essential for natural killer cell function in vivo.
J. Exp. Med.
184
:
2043
.
19
Taki, S., T. Sato, K. Ogasawara, T. Fukuda, M. Sato, S. Hida, G. Suzuki, M. Mitsuyama, E. H. Shin, S. Kojima, et al
1997
. Multistage regulation of Th1-type immune responses by the transcription factor IRF-1.
Immunity
6
:
673
.
20
Ogasawara, K., S. Hida, N. Azimi, Y. Tagaya, T. Sato, T. Yokochi-Fukuda, T. A. Waldmann, T. Taniguchi, S. Taki.
1998
. Requirement for IRF-1 in the microenvironment supporting development of natural killer cells.
Nature
391
:
700
.
21
Lohoff, M., G. S. Duncan, D. Ferrick, H. W. Mittrucker, S. Bischof, S. Prechtl, M. Rollinghoff, E. Schmitt, A. Pahl, T. W. Mak.
2000
. Deficiency in the transcription factor interferon regulatory factor (IRF)-2 leads to severely compromised development of natural killer and T helper type 1 cells.
J. Exp. Med.
192
:
325
.
22
Kitaya, K., J. Yasuda, S. Fushiki, H. Honjo.
2001
. Localization of interferon regulatory factor-1 in human endometrium throughout the menstrual cycle.
Fertil. Steril.
75
:
992
.
23
Choi, Y., G. A. Johnson, R. C. Burghardt, L. R. Berghman, M. M. Joyce, K. M. Taylor, M. D. Stewart, F. W. Bazer, T. E. Spencer.
2001
. Interferon regulatory factor-two restricts expression of interferon-stimulated genes to the endometrial stroma and glandular epithelium of the ovine uterus.
Biol. Reprod.
65
:
1038
.
24
Matsuyama, T., T. Kimura, M. Kitagawa, K. Pfeffer, T. Kawakami, N. Watanabe, T. M. Kundig, R. Amakawa, K. Kishihara, A. Wakeham, et al
1993
. Targeted disruption of IRF-1 or IRF-2 results in abnormal type I IFN gene induction and aberrant lymphocyte development.
Cell
75
:
83
.
25
Chirgwin, J. M., A. E. Przybyla, R. J. MacDonald, W. J. Rutter.
1979
. Isolation of biologically active ribonucleic acid from sources enriched in ribonuclease.
Biochemistry
18
:
5294
.
26
Liang, L., K. Kover, S. K. Dey, G. K. Andrews.
1996
. Regulation of interleukin-6 and interleukin-1β gene expression in the mouse deciduum.
J. Reprod. Immunol.
30
:
29
.
27
Rubinstein, M. P., A. N. Kadima, M. L. Salem, C. L. Nguyen, W. E. Gillanders, D. J. Cole.
2002
. Systemic administration of IL-15 augments the antigen-specific primary CD8+ T cell response following vaccination with peptide-pulsed dendritic cells.
J. Immunol.
169
:
4928
.
28
Delgado, S. R., B. A. McBey, S. Yamashiro, J. Fujita, Y. Kiso, B. A. Croy.
1996
. Accounting for the peripartum loss of granulated metrial gland cells, a natural killer cell population, from the pregnant mouse uterus.
J. Leukocyte Biol.
59
:
262
.
29
Dubois, S., J. Mariner, T. A. Waldmann, Y. Tagaya.
2002
. IL-15Rα recycles and presents IL-15 in trans to neighboring cells.
Immunity
17
:
537
.
30
Allavena, P., G. Giardina, G. Bianchi, A. Mantovani.
1997
. IL-15 is chemotactic for natural killer cells and stimulates their adhesion to vascular endothelium.
J. Leukocyte Biol.
61
:
729
.
31
Kruse, A., M. J. Merchant, R. Hallmann, E. C. Butcher.
1999
. Evidence of specialized leukocyte-vascular homing interactions at the maternal/fetal interface.
Eur. J. Immunol.
29
:
1116
.
32
Chantakru, S., W. A. Kuziel, N. Maeda, B. A. Croy.
2001
. A study on the density and distribution of uterine natural killer cells at mid pregnancy in mice genetically-ablated for CCR2, CCR5 and the CCR5 receptor ligand, MIP-1α.
J. Reprod. Immunol.
49
:
33
.
33
Hunt, J. S., L. Miller, D. Vassmer, B. A. Croy.
1997
. Expression of the inducible nitric oxide synthase gene in mouse uterine leukocytes and potential relationships with uterine function during pregnancy.
Biol. Reprod.
57
:
827
.
34
Li, X. F., D. S. Charnock-Jones, E. Zhang, S. Hiby, S. Malik, K. Day, D. Licence, J. M. Bowen, L. Gardner, A. King, et al
2001
. Angiogenic growth factor messenger ribonucleic acids in uterine natural killer cells.
J. Clin. Endocrinol. Metab.
86
:
1823
.
35
Godfrey, K. M., D. J. Barker.
2001
. Fetal programming and adult health.
Public Health Nutr.
4
:
611
.
36
Verma, S., S. E. Hiby, Y. W. Loke, A. King.
2000
. Human decidual natural killer cells express the receptor for and respond to the cytokine interleukin 15.
Biol. Reprod.
62
:
959
.
37
Chantakru, S., C. Miller, L. E. Roach, W. A. Kuziel, N. Maeda, W. C. Wang, S. S. Evans, B. A. Croy.
2002
. Contributions from self-renewal and trafficking to the uterine NK cell population of early pregnancy.
J. Immunol.
168
:
22
.
38
Lechleitner, S., J. Gille, D. R. Johnson, P. Petzelbauer.
1998
. Interferon enhances tumor necrosis factor-induced vascular cell adhesion molecule 1 (CD106) expression in human endothelial cells by an interferon-related factor 1-dependent pathway.
J. Exp. Med.
187
:
2023
.
39
Horiuchi, M., H. Yamada, M. Akishita, M. Ito, K. Tamura, V. J. Dzau.
1999
. Interferon regulatory factors regulate interleukin-1β-converting enzyme expression and apoptosis in vascular smooth muscle cells.
Hypertension
33
:
162
.
40
Wessely, R., L. Hengst, B. Jaschke, F. Wegener, T. Richter, R. Lupetti, M. Paschalidis, A. Schomig, R. Brandl, F. J. Neumann.
2003
. A central role of interferon regulatory factor-1 for the limitation of neointimal hyperplasia.
Hum. Mol. Genet.
12
:
177
.
41
Jesse, T. L., R. LaChance, M. F. Iademarco, D. C. Dean.
1998
. Interferon regulatory factor-2 is a transcriptional activator in muscle where it regulates expression of vascular cell adhesion molecule-1.
J. Cell Biol.
140
:
1265
.
42
Jabbour, H. N., H. O. Critchley, L. Y. Yu-Lee, S. C. Boddy.
1999
. Localization of interferon regulatory factor-1 (IRF-1) in nonpregnant human endometrium: expression of IRF-1 is up-regulated by prolactin during the secretory phase of the menstrual cycle.
J. Clin. Endocrinol. Metab.
84
:
4260
.